Tenpoint Therapeutics™ is actively working with eye care providers to enhance clinical and patient care for age-related ophthalmologic diseases. We are launching a new era in presbyopia treatment and developing an innovative pipeline targeting the largest areas of unmet need for rejuvenating vision in the aging eye.
02 December 2025
Tenpoint Therapeutics Ltd. To Participate in Investor Conference in December
READ MORE05 November 2025
Tenpoint Therapeutics Ltd. Announces Submission of a New Drug Application for BRIMOCHOL™ PF for the Treatment of Presbyopia to the MFDS in South Korea
READ MORE13 October 2025
Tenpoint Therapeutics Ltd., to Participate in Four Upcoming Investor Conferences
READ MORE08 September 2025
Tenpoint Therapeutics, Ltd. to Participate in Upcoming Eye Care Conferences
READ MORE25 August 2025
Tenpoint Therapeutics, Ltd. to Participate in Investor Conferences in September
READ MORE04 August 2025
Tenpoint Therapeutics Ltd. to Participate in Upcoming Investor Conferences in August
READ MORE22 July 2025
Tenpoint Therapeutics Ltd. to Participate in Virtual Presbyopia Panel Hosted by JonesTrading
READ MORE03 June 2025
Tenpoint Therapeutics Ltd. Announces FDA Acceptance of New Drug Application for BRIMOCHOL™ PF for the Treatment of Presbyopia
READ MORE02 June 2025
Tenpoint Therapeutics Ltd. Appoints Melissa Epperly as Chief Financial Officer
READ MORE23 April 2025
Tenpoint Therapeutics Ltd. to Participate at Citi Biotech Private Access Day
READ MORE08 April 2025
Tenpoint Therapeutics Ltd. Submits New Drug Application to U.S. FDA for BRIMOCHOL PF for the Treatment of Presbyopia
READ MORE31 March 2025
Tenpoint Therapeutics Ltd. to Participate in Upcoming Investor Conferences in April
READ MORE11 March 2025
Tenpoint Therapeutics Ltd. Appoints Carol Kearney as Chief Commercial Officer
READ MORE09 January 2025
Tenpoint Therapeutics Announces Positive Topline Data from Phase 3 Pivotal Study, BRIO-II, of BRIMOCHOLTM PF for the Treatment of Presbyopia
READ MORE12 December 2024
Tenpoint Therapeutics Ltd. and Visus Therapeutics, Inc. Join Forces, Building the Next Era of Best- and First-in-Class Ophthalmic Medicines
READ MORETenpoint Therapeutics™ in the news:
Tenpoint Therapeutics™ in the news:
Recent events:
